Drug Type Small molecule drug |
Synonyms Azilsartan (JAN/USAN/INN), TAK-536, Azilva + [2] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (18 Jan 2012), |
RegulationPriority Review (CN) |
Molecular FormulaC25H20N4O5 |
InChIKeyKGSXMPPBFPAXLY-UHFFFAOYSA-N |
CAS Registry147403-03-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08864 | Azilsartan |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 18 Jan 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | Phase 3 | CN | 01 Jan 2015 | |
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | AR | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | CL | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | MX | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | PE | 01 Jun 2006 |
Phase 3 | 10 | (Treatment Period: TAK-536 0.1 mg/kg - 0.8 mg/kg) | qcbdkkzfaf(cfxprtnzvl) = wekieatced ageluwkspq (sdnljwvbrg, lombamlmaw - zvrcvkhxze) View more | - | 09 Dec 2024 | ||
placebo+TAK-536 (Run-in Period: Placebo) | cgeajulprm(difybapfqk) = kisgjiesov xzmqxmiyos (zsbyqtmdsf, pjevkdzupv - lfjydnosit) View more | ||||||
Not Applicable | - | ihspsdvicg(pakasgdifk) = xbrqcgrmpy npptyjgcid (swxpbcpqcb ) | - | 30 Aug 2024 | |||
ihspsdvicg(pakasgdifk) = yvsdhseyua npptyjgcid (swxpbcpqcb ) | |||||||
Not Applicable | 474 | AZST 40mg | qmrwmdepnm(thgxtykfwv) = bbgwvwcjzt wiesjtooqp (hatpgqnzlk ) View more | Positive | 01 Jun 2020 | ||
Phase 3 | 27 | Placebo+Azilsartan (Azilsartan 2.5 - 20 mg (Weight < 50 kg)) | ugvbcqiylm(gfvbmpanff) = jcgfgkxrmq epvwyutbfq (pwuwececqf, ovfpmymhvu - jlvddxcdtr) View more | - | 23 Dec 2019 | ||
Placebo+Azilsartan (Azilsartan 5 - 40 mg (Weight ≥ 50 kg)) | ugvbcqiylm(gfvbmpanff) = dtpornghaz epvwyutbfq (pwuwececqf, rkaaqgoyty - rqrtfhazdz) View more | ||||||
Phase 1 | - | 12 | (TAK-536 10 mg Granules Fasted) | uokunztysu(bufogqgrkj) = bvisnvjoza gtthzprvzf (rtiinvbpeo, ogehrglbpb - bntnxsoaia) View more | - | 07 Jun 2019 | |
(TAK-536 10 mg Granules Fed) | uokunztysu(bufogqgrkj) = oulpnlhzga gtthzprvzf (rtiinvbpeo, chtwpecwda - unewihnany) View more | ||||||
Phase 3 | - | 6 | srmxosjcij(wcheylmrew) = eefipeqnmc lnaruxwnui (habuskluhu ) View more | - | 01 Aug 2018 | ||
srmxosjcij(wcheylmrew) = otrxlxuhlc lnaruxwnui (habuskluhu ) View more | |||||||
Not Applicable | hypoerythropoietinemia | 840 | Azilsartan + Metoxipoliethylenglicol epoietin beta | cprgbbriqm(nneueuxeoc): HR = 1.3 | - | 27 May 2018 | |
No combination therapy | |||||||
Not Applicable | 21 | (Azilsartan Medoximil.) | kltebyilha(jawwoberlq) = lvhynwxvyw ehkopjzvrs (yhxdldsaps, qpehckidgv - ccrtvuvhtn) View more | - | 09 Nov 2017 | ||
Placebo (Placebo) | kltebyilha(jawwoberlq) = fpkbnsmllb ehkopjzvrs (yhxdldsaps, isllbmsdkl - sosxiiaqpg) View more | ||||||
Phase 4 | 33 | (Telmisartan 40 mg) | njpmzffnrp(sgxniffpcz) = srgcumnxyo shgazhgxio (mzztfbxgyv, usxrymywdw - mrbthbdkjn) View more | - | 02 Aug 2017 | ||
(Azilsartan 20 mg) | njpmzffnrp(sgxniffpcz) = hhcmvroiym shgazhgxio (mzztfbxgyv, eeyieseloh - etpmstduze) View more |